Current News

September 19, 2017

Morphotek to Present Preclinical Data on Antibody-Drug Conjugate MORAb-202 at the Upcoming 8th Annual World ADC in San Diego
Read More

September 6, 2017

Morphotek Announces Collaboration Agreement with the Johns Hopkins University to Research and Develop Novel Monoclonal Antibody-Based Therapies Targeting Missplicing-Associated Surface Antigens
Read More

September 5, 2017

Morphotek, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc to Commercialize the CA125 II Assay as A Companion Diagnostic for Farletuzumab
Read More

July 11, 2017

Morphotek Announces Publication Uncovering One of the Mechanisms by Which the Tumor-Produced CA125 Protein Suppresses Immune-Mediated Killing Via Farletuzumab
Read More

April 26, 2017

Morphotek to Present its Proprietary RESPECT Antibody Drug Conjugate (ADC) Technology at the Upcoming 13th Annual PEGS Summit in Boston
Read More

April 3, 2017

Morphotek Launches Antibody Drug Conjugate Services Business
Read More

March 28, 2017

Morphotek to Present Three Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting 2017
Read More

March 22, 2017

Morphotek and Sandy Rollman Ovarian Cancer Foundation Launch Educational Resource on Clinical Trials
Read More

October 3, 2016

Morphotek and Eurofarma Laboratorios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America
Read More

September 13, 2016

Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center to Study Immunosuppressive Effects of Tumor Shed Antigens to Improve Future Patient Therapies
Read More

Displaying results 1-10 (of 132)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >| 

News & Events > News Archive